Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,471 across all filing types
Latest filing 2021-12-28 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed data on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content is focused on reporting share repurchase transactions and capital changes rather than financial results, management changes, or other report types. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is over 12,000 characters and contains substantive data on share repurchases, not just an announcement or certification, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2021-12-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase activities and changes in share capital, which aligns with announcements regarding transactions in own shares. There is no indication that this is a full financial report, earnings release, or regulatory certification. The document is not a report publication announcement but a detailed disclosure of share repurchase transactions. Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS).
2021-12-24 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules of the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases and capital changes, not a financial report or earnings release. It is not an announcement of a report publication but a formal regulatory filing about share capital changes and repurchases. This fits the definition of 'Transaction in Own Shares' (POS) which covers reports of the company buying back or selling its own shares.
2021-12-23 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules of the Stock Exchange of Hong Kong. The content is focused on reporting share repurchase transactions and capital changes, not on financial results, management commentary, or other report types. The document is over 12,000 characters, indicating it is a substantive disclosure rather than a brief announcement. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares.
2021-12-22 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules of the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases and capital changes, not a financial report or earnings release. It is not a report publication announcement since it contains substantive data about share repurchases. The content fits the definition of a 'Transaction in Own Shares' filing, which reports the company's buyback activities.
2021-12-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules of the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases, not a full financial report or earnings release. It fits the description of a report on the company buying back its own shares. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail support a confident classification.
2021-12-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.